Advertisement
Advertisement
U.S. markets open in 6 hours 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
13.38-0.04 (-0.32%)
At close: 9:57AM EST
Advertisement

Inventiva S.A.

50 rue de Dijon
Daix 21121
France
33 3 80 44 75 00
http://www.inventivapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees100

Key Executives

NameTitlePayExercisedYear Born
Mr. Frederic CrenCo-Founder, CEO & Chairman438.83kN/A1966
Dr. Pierre BroquaCo-Founder, Chief Scientific Officer, Deputy CEO & Director332.9kN/A1962
Mr. Jean VolatierChief Financial OfficerN/AN/A1964
Mr. Eric Duranson L.L.M.Gen. CounselN/AN/AN/A
Ms. Nathalie HarroyHead of HRN/AN/AN/A
Dr. Olivier Lacombe PH.D.Head of PharmacokineticsN/AN/AN/A
Dr. Christian Montalbetti PH.D.Head of ChemistryN/AN/AN/A
Dr. Irena KonstantinovaHead of Biology & PharmacologyN/AN/AN/A
Dr. Michael CooremanChief Medical OfficerN/AN/A1958
Mr. Jean-Paul Dutertre M.D.Head of PharmacovigilanceN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Corporate Governance

Inventiva S.A.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement